Efficacy of Biosimilar Pegylated Interferon Alpha 40 KD (Peg INF) in Chronic Hepatitis C Infection

Authors: Ghias ul Hassan, Bilal Nasir, Israr ul Haque, ShafiqAwan, Ghias Un NabiTayyab, S. Hassan Akhtar Bokhari, Khawar Saeed, Qazi Masroor

Abstract:

Introduction: Pegylated Interferon and Ribavirin combination is standard of care in the management of chronic HCV infected patients. Efficacy of the therapy is judged by the ability to achieve biochemical and virological response as judged by RVR, EVR, ETR and SVR.Objective: To evaluate the efficacy of newly marketed biosimilar Pegylated Interferon Alpha 40KD (Peg INF) in chronic HCV patients. Materials and methods: This was observational, prospective multicentre study to evaluate the ability of biosimilar pegylated interferon alfa 2a (40KD) along with Ribavirin (weight based) to achieve SVR. The enrolled patients were separated into Naïve (A), Relapsers (B) and Non Responders(C) based on the previous history of interferon exposure and its response. The RGT was followed on ALT and RVR, EVR, ETR and SVR.Results:As per protocol analysis estimated SVR for three groups is 86.6% for naïve, 89.4% for relapsers and 52.4% for non-responders to standard interferon. Conclusion: It is concluded that Bio-similar pegylated interferon alfa-2a (40kD) along with Ribavirin has good anti-viral efficacy in Naïve, Relapsers and Non-responders to standard IFN of chronic HCV infected patients requiring treatment.

Keywords: SVR (Sustained virological response), NR (Nonresponders), Pegylated Interferon.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1089639

References:

[1] M. Umar, M Bilal, Hepatitis C, A Mega Menace: A Pakistani Perspective –JPMS, vol. 2, no. 2, 2012.
[2] M. G. Ghany, D. B. Strader, D. L. Thomas, L. B. Seeff, "Diagnosis, management, and treatment of hepatitis C: an update”, Hepatol., vol. 49 no. 4, pp. 1335-1374, Apr. 2009.
[3] S. A. Gonzalez, E. B. Keeffe. "Management of chronic hepatitis C treatment failures: role of consensus interferon,”.Biologics, vol. 3, pp. 141-150, 2009.
[4] B. Horoldt, G. Haydon, K. O'Donnell, T. Dudley, P. Nightingale, D. Mutimer, "Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection,” Liver Int., vol. 26, no. 6, pp. 650-659, Aug. 2006.
[5] M. P. Manns, J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, et al., "Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial,” Lancet, vol. 22, no. 358(9286), pp. 958-965, Sep. 2001.
[6] M. W. Fried, M. L. Shiffman, K. R. Reddy, C. Smith, G.Marinos, F. L. Goncales, Jr., et al., "Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection,” N Engl J Med.,vol. 26, no. 347(13) pp. 975-982, Sep. 2002.
[7] S. J. Hadziyannis, H. Sette, Jr., T. R.Morgan, V. Balan, M. Diago, P. Marcellin et al.,"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Ann Intern Med., vol. 2, no. 140(5), pp. 346-355. Mar. 2004.
[8] W. Jafri, A. Subhan, "Hepatitis C in Pakistan: magnitude, genotype, disease characteristics and therapeutic response,” Trop Gastroenterol., vol. 29, no. 4, pp. 194-201. Oct-Dec. 2008.
[9] Joep MA Lange, Douglas D Richman, et al. Antiviral Therapy: Prophesys Academy Supplement: on course for success.2008; 13: Suppl 1:3-8.
[10] Jabbari, F. Zamani, K. Hatami, A. Sheikholeslami, E. Fakharzadeh, K. Shahzamani et al., "Pegaferon in hepatitis C: Results of a Multicenter Study,” Mid East J Dig Dis., vol. 3, no. 2, pp. 110-111, Sept. 2011.
[11] Jabbari H, Bayatian A, Shari AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R. Safety and ef_cacy of locally manufactured pegylated interferon in hepatitis C patients. ArchIran Med 2010;4:306-12.
[12] Chen-Hua L, Chun-Jen L, Chih-Lin L, Cheng-Chao L, Shih-Jer H, Sheng-Shun Y,et al. Pegylated Interferon-a- 2a plus Ribavirin for Treatment-Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial. ClinInf Dis 2008;47:1260-9.
[13] Carla WB, Andrew JM. The impact of race and ethnicity on the treatment of hepatitis C disease. Current HepatitisReports2006;5:79-85.
[14] Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002;36:1259-65.
[15] Missiha S, Heathcote J, Arenovich T, Khan K; Canadian Pegasys Expanded Access Group Impact of asian race on response to combination therapy with peginterferonalfa- 2a and ribavirin in chronic hepatitis C. Am J Gastroenterol. 2007;102:2181.